Top

Current Neurology and Neuroscience Reports

Published in:

01-03-2021 | Myasthenia Gravis | Neurology of Systemic Diseases (J. Biller, Section Editor)

Peripheral Nervous System Manifestations Associated with COVID-19

Authors: Sasan Andalib, José Biller, Mario Di Napoli, Narges Moghimi, Louise D McCullough, Clio A. Rubinos, Christa O’Hana Nobleza, M. Reza Azarpazhooh, Luciana Catanese, Isabel Elicer, Mostafa Jafari, Fabrizio Liberati, Claudia Camejo, Michel Torbey, Afshin A. Divani

Published in: Current Neurology and Neuroscience Reports | Issue 3/2021

Abstract

Purpose of Review

The present review discusses the peripheral nervous system (PNS) manifestations associated with coronavirus disease 2019 (COVID-19).

Recent Findings

Nerve pain and skeletal muscle injury, Guillain-Barré syndrome, cranial polyneuritis, neuromuscular junction disorders, neuro-ophthalmological disorders, neurosensory hearing loss, and dysautonomia have been reported as PNS manifestations in patients with COVID-19.

Summary

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19. COVID-19 has shown syndromic complexity. Not only does SARS-CoV-2 affect the central nervous system but also it involves the PNS. The PNS involvement may be due to dysregulation of the immune system attributable to COVID-19. Here we review the broad spectrum of PNS involvement of COVID-19.

He F, Deng Y, Li W. Coronavirus disease 2019: what we know? J Med Virol. 2020;92(7):719–25. https://doi.org/10.1002/jmv.25766.CrossRefPubMed

Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020;92:568–76. https://doi.org/10.1002/jmv.25748.CrossRefPubMed

• Divani AA, Andalib S, Biller J, Napoli DM, Moghimi N, Rubinos CA, et al. Central nervous system manifestations associated with COVID-19. Curr Neurol Neurosci Rep. 2020;20(12):60. https://doi.org/10.1007/s11910-020-01079-7A review focusing of centeral nervous system manifestations of COVID-19.CrossRefPubMedPubMedCentral

Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87(5):E1–9. https://doi.org/10.1161/01.res.87.5.e1.CrossRefPubMed

Ohtsuki M, Morimoto SI, Izawa H, Ismail TF, Ishibashi-Ueda H, Kato Y, et al. Angiotensin converting enzyme 2 gene expression increased compensatory for left ventricular remodeling in patients with end-stage heart failure. Int J Cardiol. 2010;145(2):333–4. https://doi.org/10.1016/j.ijcard.2009.11.057.CrossRefPubMed

Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275(43):33238–43. https://doi.org/10.1074/jbc.M002615200.CrossRefPubMed

Ferrario CM, Varagic J. The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function. Am J Physiol Renal Physiol. 2010;298(6):F1297–305. https://doi.org/10.1152/ajprenal.00110.2010.CrossRefPubMedPubMedCentral

Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol. 2020;92(7):726–30. https://doi.org/10.1002/jmv.25785.CrossRefPubMedPubMedCentral

Iadecola C, Anrather J, Kamel H. Effects of COVID-19 on the nervous system. Cell. 2020;183(1):16–27.e1. https://doi.org/10.1016/j.cell.2020.08.028.CrossRefPubMedPubMedCentral

10.

• Divani AA, Andalib S, Di Napoli M, Lattanzi S, Hussain MS, Biller J, et al. Coronavirus disease 2019 and stroke: clinical manifestations and pathophysiological insights. J Stroke Cerebrovasc Dis. 2020;29(8):104941. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104941A review summarizing the clinical and pathophysiological aspects of stroke in COVID-19.CrossRefPubMedPubMedCentral

11.

Bilinska K, Jakubowska P, Von Bartheld CS, Butowt R. Expression of the SARS-CoV-2 entry proteins, ACE2 and TMPRSS2, in cells of the olfactory epithelium: identification of cell types and trends with age. ACS Chem Neurosci. 2020;11(11):1555–62. https://doi.org/10.1021/acschemneuro.0c00210.CrossRefPubMed

12.

de Freitas Ferreira ACA, Romão TT, Silva Macedo Y, Pupe C, Nascimento OJ. COVID-19 and herpes zoster co-infection presenting with trigeminal neuropathy. Eur J Neurol. 2020. https://doi.org/10.1111/ene.14361.

13.

Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol. 2020;77(8):1018–27. https://doi.org/10.1001/jamaneurol.2020.2065.CrossRefPubMedPubMedCentral

14.

Matschke J, Lütgehetmann M, Hagel C, Sperhake JP, Schröder AS, Edler C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020;19(11):919–29. https://doi.org/10.1016/s1474-4422(20)30308-2.CrossRefPubMedPubMedCentral

15.

Schurink B, Roos E, Radonic T, Barbe E, Bouman CSC, de Boer HH, et al. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe. 2020;1(7):e290–e9. https://doi.org/10.1016/s2666-5247(20)30144-0.CrossRefPubMedPubMedCentral

16.

Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. bioRxiv. 2020. https://doi.org/10.1101/2020.06.25.169946.

17.

Solomon IH, Normandin E, Bhattacharyya S, Mukerji SS, Keller K, Ali AS, et al. Neuropathological features of Covid-19. N Engl J Med. 2020. https://doi.org/10.1056/NEJMc2019373.

18.

Fajgenbaum DC, June CH. Cytokine Storm. NEJM. 2020;383(23):2255–73. https://doi.org/10.1056/NEJMra2026131.CrossRefPubMed

19.

Vaninov N. In the eye of the COVID-19 cytokine storm. Nat Rev Immunol. 2020;20:277. https://doi.org/10.1038/s41577-020-0305-6.CrossRefPubMed

20.

Conti P, Ronconi G, Caraffa A, Gallenga C, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2). https://doi.org/10.23812/CONTI-E.

21.

Marchetti C, Swartzwelter B, Koenders MI, Azam T, Tengesdal IW, Powers N, et al. NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis. Arthritis Res Ther. 2018;20(1):169. https://doi.org/10.1186/s13075-018-1664-2.CrossRefPubMedPubMedCentral

22.

Payus AO, Lin CLS, Noh MM, Jeffree MS, RAJBJoBMS A. SARS-CoV-2 infection of the nervous system: a review of the literature on neurological involvement in novel coronavirus disease (COVID-19). Bosn J Basic Med Sci. 2020;20(3):283–92. https://doi.org/10.17305/bjbms.2020.4860.CrossRefPubMedPubMedCentral

23.

Kany S, Vollrath JT, Relja B. Cytokines in inflammatory disease. Int J Mol Sci. 2019;20(23). https://doi.org/10.3390/ijms20236008.

24.

Shaafi S, Sharifipour E, Rahmanifar R, Hejazi S, Andalib S, Nikanfar M, et al. Interleukin-6, a reliable prognostic factor for ischemic stroke. Iran J Neurol. 2014;13(2):70–6.PubMedPubMedCentral

25.

Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7). https://doi.org/10.1128/jvi.00127-20.

26.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/s0140-6736(20)30183-5.CrossRefPubMedPubMedCentral

27.

McNab F, Mayer-Barber K, Sher A, Wack A, O’garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15(2):87–103. https://doi.org/10.1038/nri3787.CrossRefPubMedPubMedCentral

28.

Alberti P, Beretta S, Piatti M, Karantzoulis A, Piatti ML, Santoro P, et al. Guillain-Barré syndrome related to COVID-19 infection. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e741. https://doi.org/10.1212/NXI.0000000000000741.

29.

Studart-Neto A, Guedes BF, Tuma RLE, Camelo Filho AE, Kubota GT, Iepsen BD, et al. Neurological consultations and diagnoses in a large, dedicated COVID-19 university hospital. Arquivos de neuro-psiquiatria. 2020;78(8):494–500. https://doi.org/10.1590/0004-282x20200089.CrossRefPubMed

30.

McGonagle D, Sharif K, O’Regan A, Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020;19(6):102537. https://doi.org/10.1016/j.autrev.2020.102537.CrossRefPubMedPubMedCentral

31.

Needham E, Newcombe V, Michell A, Thornton R, Grainger A, Anwar F, et al. Mononeuritis multiplex: an unexpectedly frequent feature of severe COVID-19. Journal of Neurology. 2020. https://doi.org/10.1007/s00415-020-10321-8.

32.

Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717–27. https://doi.org/10.1016/s0140-6736(16)00339-1.CrossRefPubMed

33.

Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K, Ferreira MLB, Cornblath DR, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671–83. https://doi.org/10.1038/s41582-019-0250-9.CrossRefPubMedPubMedCentral

34.

Kim JE, Heo JH, Kim HO, Song SH, Park SS, Park TH, et al. Neurological complications during treatment of Middle East respiratory syndrome. J Clin Neurol. 2017;13(3):227–33. https://doi.org/10.3988/jcn.2017.13.3.227.CrossRefPubMedPubMedCentral

35.

Tsai LK, Hsieh ST, Chang YC. Neurological manifestations in severe acute respiratory syndrome. Acta Neurol Taiwan. 2005;14(3):113–9.PubMed

36.

Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. 2020;19(5):383–4. https://doi.org/10.1016/S1474-4422(20)30109-5.CrossRefPubMedPubMedCentral

37.

Abdelnour L, Eltahir Abdalla M, Babiker S. COVID 19 infection presenting as motor peripheral neuropathy. J Formos Med Assoc. 2020;119(6):1119–20. https://doi.org/10.1016/j.jfma.2020.04.024.CrossRefPubMedPubMedCentral

38.

Caress JB, Castoro RJ, Simmons Z, Scelsa SN, Lewis RA, Ahlawat A, et al. COVID-19-associated Guillain-Barré syndrome: the early pandemic experience. Muscle Nerve. 2020;62(4):485–91. https://doi.org/10.1002/mus.27024.CrossRefPubMed

39.

Zito A, Alfonsi E, Franciotta D, Todisco M, Gastaldi M, Cotta Ramusino M, et al. COVID-19 and Guillain-Barré syndrome: a case report and review of literature. Front Neurol. 2020;11:909. https://doi.org/10.3389/fneur.2020.00909.CrossRefPubMedPubMedCentral

40.

Virani A, Rabold E, Hanson T, Haag A, Elrufay R, Cheema T, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection. IDCases. 2020:e00771. https://doi.org/10.1016/j.idcr.2020.e00771.

41.

Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain–Barré syndrome associated with SARS-CoV-2. N Eng J Med. 2020;382:2574–6. https://doi.org/10.1056/NEJMc2009191.CrossRef

42.

Chan JL, Ebadi H, Sarna JR. Guillain-Barré syndrome with facial diplegia related to SARS-CoV-2 infection. Can J Neurol Sci. 2020:1–3. https://doi.org/10.1017/cjn.2020.106.

43.

Hutchins KL, Jansen JH, Comer AD, Scheer RV, Zahn GS, Capps AE, et al. COVID-19-associated bifacial weakness with paresthesia subtype of Guillain-Barré syndrome. Am J Neuroradiol. 2020;41(9):1707–11. https://doi.org/10.3174/ajnr.a6654.CrossRefPubMed

44.

Ottaviani D, Boso F, Tranquillini E, Gapeni I, Pedrotti G, Cozzio S, et al. Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital. Neurol Sci. 2020:1–4. https://doi.org/10.1007/s10072-020-04449-8.

45.

Juliao Caamaño DS, Alonso Beato R. Facial diplegia, a possible atypical variant of Guillain-Barré Syndrome as a rare neurological complication of SARS-CoV-2. J Clin Neurosci. 2020. https://doi.org/10.1016/j.jocn.2020.05.016.

46.

Padroni M, Mastrangelo V, Asioli GM, Pavolucci L, Abu-Rumeileh S, Piscaglia MG, et al. Guillain-Barré syndrome following COVID-19: new infection, old complication? J Neurol. 2020:1–3. https://doi.org/10.1007/s00415-020-09849-6.

47.

Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: A case report. J Clin Neurosci. 2020:S0967-5868(20)30882-1. https://doi.org/10.1016/j.jocn.2020.04.062.

48.

Coen M, Jeanson G, Culebras Almeida LA, Hübers A, Stierlin F, Najjar I, et al. Guillain-Barré syndrome as a complication of SARS-CoV-2 infection. Brain Behav Immun. 2020:S0889-1591(20)30698-X. https://doi.org/10.1016/j.bbi.2020.04.074.

49.

Camdessanche JP, Morel J, Pozzetto B, Paul S, Tholance Y, Botelho-Nevers E. COVID-19 may induce Guillain-Barré syndrome. Rev Neurol (Paris). 2020;176(6):516–8. https://doi.org/10.1016/j.neurol.2020.04.003.CrossRefPubMedPubMedCentral

50.

Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Mañas R, et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020. https://doi.org/10.1212/wnl.0000000000009619.

51.

Lantos JE, Strauss SB, Lin E. COVID-19-associated Miller Fisher syndrome: MRI findings. AJNR Am J Neuroradiol. 2020;41(7):1184–6. https://doi.org/10.3174/ajnr.A6609.CrossRefPubMed

52.

Rana S, Lima AA, Chandra R, Valeriano J, Desai T, Freiberg W et al. Novel Coronavirus (COVID-19)-associated Guillain-Barré syndrome: case report. J Clin Neuromuscul Dis. 2020;21(4):240-2. doi:https://doi.org/10.1097/CND.0000000000000309.

53.

Reyes-Bueno JA, García-Trujillo L, Urbaneja P, Ciano-Petersen NL, Postigo-Pozo MJ, Martínez-Tomás C, et al. Miller-Fisher syndrome after SARS-CoV-2 infection. Eur J Neurol. 2020. https://doi.org/10.1111/ene.14383.

54.

Senel M, Abu-Rumeileh S, Michel D, Garibashvili T, Althaus K, Kassubek J, et al. Miller-Fisher syndrome after COVID-19: neurochemical markers as an early sign of nervous system involvement. Eur J Neurol. 2020;27(11):2378–80. https://doi.org/10.1111/ene.14473.CrossRefPubMed

55.

Fernández-Domínguez J, Ameijide-Sanluis E, García-Cabo C, García-Rodríguez R, Mateos V. Miller-Fisher-like syndrome related to SARS-CoV-2 infection (COVID 19). J Neurol. 2020;267(9):2495–6. https://doi.org/10.1007/s00415-020-09912-2.CrossRefPubMed

56.

Manganotti P, Pesavento V, Buoite Stella A, Bonzi L, Campagnolo E, Bellavita G, et al. Miller Fisher syndrome diagnosis and treatment in a patient with SARS-CoV-2. J Neurovirol. 2020;26(4):605–6. https://doi.org/10.1007/s13365-020-00858-9.CrossRefPubMed

57.

Diez-Porras L, Vergés E, Gil F, Vidal MJ, Massons J, Arboix A. Guillain-Barré-Strohl syndrome and COVID-19: case report and literature review. Neuromuscular disorders : NMD. 2020:S0960-8966(20)30551-4. https://doi.org/10.1016/j.nmd.2020.08.354.

58.

Paybast S, Gorji R, Mavandadi S. Guillain-Barré syndrome as a neurological complication of novel COVID-19 infection: a case report and review of the literature. The neurologist. 2020;25(4):101–3. https://doi.org/10.1097/NRL.0000000000000291.CrossRefPubMed

59.

Assini A, Benedetti L, Di Maio S, Schirinzi E, Del Sette M. New clinical manifestation of COVID-19 related Guillain-Barrè syndrome highly responsive to intravenous immunoglobulins: two Italian cases. Neurol Sci. 2020;41(7):1657–8. https://doi.org/10.1007/s10072-020-04484-5.CrossRefPubMed

60.

Su XW, Palka SV, Rao RR, Chen FS, Brackney CR, Cambi F. SARS-CoV-2-associated Guillain-Barré syndrome with dysautonomia. Muscle Nerve. 2020;62(2):E48–e9. https://doi.org/10.1002/mus.26988.CrossRefPubMed

61.

Scheidl E, Canseco DD, Hadji-Naumov A, Bereznai B. Guillain-Barré syndrome during SARS-CoV-2 pandemic: a case report and review of recent literature. J Peripher Nerv Syst. 2020;25(2):204–7. https://doi.org/10.1111/jns.12382.CrossRefPubMed

62.

Oguz-Akarsu E, Ozpar R, Mirzayev H, Acet-Ozturk NA, Hakyemez B, Ediger D, et al. Guillain-Barré syndrome in a patient with minimal symptoms of COVID-19 infection. Muscle & nerve. 2020;62(3):E54–E7. https://doi.org/10.1002/mus.26992.CrossRef

63.

El Otmani H, El Moutawakil B, Rafai MA, El Benna N, El Kettani C, Soussi M, et al. Covid-19 and Guillain-Barré syndrome: more than a coincidence! Rev Neurol (Paris). 2020;176(6):518–9. https://doi.org/10.1016/j.neurol.2020.04.007.CrossRefPubMedPubMedCentral

64.

Bigaut K, Mallaret M, Baloglu S, Nemoz B, Morand P, Baicry F, et al. Guillain-Barré syndrome related to SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e785. https://doi.org/10.1212/nxi.0000000000000785.CrossRefPubMedPubMedCentral

65.

Arnaud S, Budowski C, Ng Wing Tin S, Degos B. Post SARS-CoV-2 Guillain-Barré syndrome. Clin Neurophysiol. 2020;131(7):1652–4. https://doi.org/10.1016/j.clinph.2020.05.003.CrossRefPubMedPubMedCentral

66.

Esteban Molina A, Mata Martínez M, Sánchez Chueca P, Carrillo López A, Sancho Val I, Sanjuan-Villarreal TA. Guillain-Barré syndrome associated with SARS-CoV-2 infection. Med Intensiva. 2020;44(8):513–4. https://doi.org/10.1016/j.medin.2020.04.015.CrossRefPubMedPubMedCentral

67.

Marta-Enguita J, Rubio-Baines I, Gastón-Zubimendi I. Fatal Guillain-Barre syndrome after infection with SARS-CoV-2. Neurologia. 2020;35(4):265–7. https://doi.org/10.1016/j.nrl.2020.04.004.CrossRefPubMedPubMedCentral

68.

Sancho-Saldaña A, Lambea-Gil Á, Liesa JLC, Caballo MRB, Garay MH, Celada DR, et al. Guillain-Barré syndrome associated with leptomeningeal enhancement following SARS-CoV-2 infection. Clin Med (Lond). 2020;20(4):e93–e4. https://doi.org/10.7861/clinmed.2020-0213.CrossRef

69.

Velayos Galán A, del Saz Saucedo P, Peinado Postigo F, Botia Paniagua E. Guillain-Barré syndrome associated with SARS-CoV-2 infection. Neurología (English Edition). 2020;35(4):268–9. https://doi.org/10.1016/j.nrleng.2020.04.006.CrossRefPubMedCentral

70.

Webb S, Wallace VC, Martin-Lopez D, Yogarajah M. Guillain-Barré syndrome following COVID-19: a newly emerging post-infectious complication. BMJ Case Reports. 2020;13(6):e236182. https://doi.org/10.1136/bcr-2020-236182.CrossRefPubMedPubMedCentral

71.

•• Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, Sánchez-Larsen Á, Layos-Romero A, García-García J, et al. Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry. Neurology. 2020. https://doi.org/10.1212/WNL.0000000000009937ALBACOVID registry reported myalgias, myopathy, and optic neuritis in patients with COVID-19.

72.

•• De Sanctis P, Doneddu PE, Viganò L, Selmi C, Nobile-Orazio E. Guillain-Barré syndrome associated with SARS-CoV-2 infection. A systematic review. Eur J Neurol. 2020. https://doi.org/10.1111/ene.14462A systematic review giving account of Guillain-Barré syndrome (GBS) associated with COVID-19.

73.

Gupta A, Paliwal VK, Garg RK. Is COVID-19-related Guillain-Barré syndrome different? Brain Behav Immun. 2020;87:177–8. https://doi.org/10.1016/j.bbi.2020.05.051.CrossRefPubMedPubMedCentral

74.

Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2020:1–38. https://doi.org/10.1007/s00415-020-10124-x.

75.

Uncini A, Vallat JM, Jacobs BC. Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. J Neurol Neurosurg Psychiatry. 2020;91(10):1105–10. https://doi.org/10.1136/jnnp-2020-324491.CrossRefPubMed

76.

Keddie S, Pakpoor J, Mousele C, Pipis M, Machado PM, Foster M, et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain. 2020. https://doi.org/10.1093/brain/awaa433.

77.

Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–90. https://doi.org/10.1001/jamaneurol.2020.1127.CrossRefPubMed

78.

Han YN, Feng ZW, Sun LN, Ren XX, Wang H, Xue YM, et al. A comparative-descriptive analysis of clinical characteristics in 2019-coronavirus-infected children and adults. J Med Virol. 2020. https://doi.org/10.1002/jmv.25835.

79.

Wang X, Liu W, Zhao J, Lu Y, Wang X, Yu C, et al. Clinical characteristics of 80 hospitalized frontline medical workers infected with COVID-19 in Wuhan, China. J Hosp Infect. 2020;105(3):399–403. https://doi.org/10.1016/j.jhin.2020.04.019.CrossRefPubMedCentral

80.

Liu M, He P, Liu HG, Wang XJ, Li FJ, Chen S, et al. Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(3):209–14. https://doi.org/10.3760/cma.j.issn.1001-0939.2020.03.014.CrossRefPubMed

81.

Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. 2020;288(3):335–44. https://doi.org/10.1111/joim.13089.CrossRefPubMed

82.

Lai X, Wang M, Qin C, Tan L, Ran L, Chen D, et al. Coronavirus disease 2019 (COVID-2019) infection among health care workers and implications for prevention measures in a tertiary hospital in Wuhan, China. JAMA network open. 2020;3(5):e209666-e. https://doi.org/10.1001/jamanetworkopen.2020.9666.CrossRef

83.

Lapostolle F, Schneider E, Vianu I, Dollet G, Roche B, Berdah J, et al. Clinical features of 1487 COVID-19 patients with outpatient management in the Greater Paris: the COVID-call study. Intern Emerg Med. 2020;15(5):813–7. https://doi.org/10.1007/s11739-020-02379-z.CrossRefPubMed

84.

Chen Y, Zhao M, Wu Y, Zang S. Epidemiological analysis of the early 38 fatalities in Hubei, China, of the coronavirus disease 2019. J Glob Health. 2020;10(1):011004. https://doi.org/10.7189/jogh-10-011004.CrossRefPubMedPubMedCentral

85.

O’Reilly GM, Mitchell RD, Wu J, Rajiv P, Bannon-Murphy H, Amos T, et al. Epidemiology and clinical features of emergency department patients with suspected COVID-19: results from the first month of the COVID-19 Emergency Department Quality Improvement Project (COVED-2). Emerg Med Australas. 2020;32(5):814–22. https://doi.org/10.1111/1742-6723.13573.CrossRefPubMed

86.

Gaur A, Meena SK, Bairwa R, Meena D, Nanda R, Sharma SR, et al. Clinico-radiological Presentation of COVID-19 Patients at a Tertiary Care Center at Bhilwara Rajasthan, India. J Assoc Physicians India. 2020;68(7):29–33.PubMed

87.

Aggarwal A, Shrivastava A, Kumar A, Ali A. Clinical and Epidemiological Features of SARS-CoV-2 Patients in SARI Ward of a Tertiary Care Centre in New Delhi. J Assoc Physicians India. 2020;68(7):19–26.PubMed

88.

Xu X-W, Wu X-X, Jiang X-G, Xu K-J, Ying L-J, Ma C-L, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ (Clinical research ed). 2020;368:m606-m. https://doi.org/10.1136/bmj.m606.CrossRef

89.

Wei X-S, Wang X-R, Zhang J-C, Yang W-B, Ma W-L, Yang B-H, et al. A cluster of health care workers with COVID-19 pneumonia caused by SARS-CoV-2. J Microbiol Immunol Infect. 2020:S1684-182(20)30107-9. https://doi.org/10.1016/j.jmii.2020.04.013.

90.

Korkmaz MF, Türe E, Dorum BA, Kılıç ZB. The epidemiological and clinical characteristics of 81 children with COVID-19 in a pandemic hospital in Turkey: an observational cohort study. Journal of Korean medical science. 2020;35(25):e236-e. https://doi.org/10.3346/jkms.2020.35.e236.CrossRef

91.

Beydon M, Chevalier K, Al Tabaa O, Hamroun S, Delettre AS, Thomas M, et al. Myositis as a manifestation of SARS-CoV-2. Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-217573.

92.

Zhang H, Charmchi Z, Seidman RJ, Anziska Y, Velayudhan V, Perk J. COVID-19-associated myositis with severe proximal and bulbar weakness. Muscle Nerve. 2020;62(3):E57–60. https://doi.org/10.1002/mus.27003.CrossRefPubMed

93.

Mehan WA, Yoon BC, Lang M, Li MD, Rincon S, Buch K. Paraspinal myositis in patients with COVID-19 infection. AJNR Am J Neuroradiol. 2020;41(10):1949–52. https://doi.org/10.3174/ajnr.A6711.CrossRefPubMed

94.

Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018;20(4):21. https://doi.org/10.1007/s11926-018-0732-6.CrossRefPubMedPubMedCentral

95.

Vaira LA, Deiana G, Fois AG, Pirina P, Madeddu G, De Vito A, et al. Objective evaluation of anosmia and ageusia in COVID-19 patients: single-center experience on 72 cases. Head Neck. 2020;42(6):1252–8. https://doi.org/10.1002/hed.26204.CrossRefPubMedPubMedCentral

96.

Homma Y, Watanabe M, Inoue K, Moritaka T. Coronavirus Disease-19 Pneumonia with Facial Nerve Palsy and Olfactory Disturbance. Intern Med. 2020;59(14):1773–5. https://doi.org/10.2169/internalmedicine.5014-20.CrossRefPubMedPubMedCentral

97.

Gogia B, Gil Guevara A, Rai PK, Fang X. A case of COVID-19 with multiple cranial neuropathies. Int J Neurosci. 2020:1–3. https://doi.org/10.1080/00207454.2020.1869001.

98.

Restivo DA, Centonze D, Alesina A, Marchese-Ragona R. Myasthenia gravis associated with SARS-CoV-2 infection. Ann Intern Med. 2020;173(12):1027–8. https://doi.org/10.7326/L20-0845.CrossRefPubMed

99.

Gilhus NE, Romi F, Hong Y, Skeie GO. Myasthenia gravis and infectious disease. J Neurol. 2018;265(6):1251–8. https://doi.org/10.1007/s00415-018-8751-9.CrossRefPubMed

100.

Camelo-Filho AE, Silva AMS, Estephan EP, Zambon AA, Mendonça RH, Souza PVS, et al. Myasthenia gravis and COVID-19: clinical characteristics and outcomes. Front Neurol. 2020;11:1053. https://doi.org/10.3389/fneur.2020.01053.CrossRefPubMedPubMedCentral

101.

Delly F, Syed MJ, Lisak RP, Zutshi D. Myasthenic crisis in COVID-19. J Neurol Sci. 2020;414:116888. https://doi.org/10.1016/j.jns.2020.116888.CrossRefPubMedPubMedCentral

102.

Marie I, Maurey G, Hervé F, Hellot MF, Levesque H. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol. 2006;155(4):714–21. https://doi.org/10.1111/j.1365-2133.2006.07390.x.CrossRefPubMed

103.

Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–7. https://doi.org/10.1016/j.thromres.2020.04.013.CrossRefPubMedPubMedCentral

104.

Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard JF Jr, et al. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020;412:116803. https://doi.org/10.1016/j.jns.2020.116803.CrossRefPubMedPubMedCentral

105.

Marinho PM, Marcos AAA, Romano AC, Nascimento H, Belfort R Jr. Retinal findings in patients with COVID-19. Lancet (London, England). 2020. https://doi.org/10.1016/S0140-6736(20)31014-X.

106.

Dinkin M, Gao V, Kahan J, Bobker S, Simonetto M, Wechsler P, et al. COVID-19 presenting with ophthalmoparesis from cranial nerve palsy. Neurology. 2020;95(5):221–3. https://doi.org/10.1212/wnl.0000000000009700.CrossRefPubMed

107.

Belghmaidi S, Nassih H, Boutgayout S, El Fakiri K, El Qadiry R, Hajji I, et al. Third cranial nerve palsy presenting with unilateral diplopia and strabismus in a 24-year-old woman with COVID-19. Am J Case Rep. 2020;21:e925897. https://doi.org/10.12659/ajcr.925897.CrossRefPubMedPubMedCentral

108.

Munro KJ, Uus K, Almufarrij I, Chaudhuri N, Yioe V. Persistent self-reported changes in hearing and tinnitus in post-hospitalisation COVID-19 cases. Int J Audiol. 2020:1–2. https://doi.org/10.1080/14992027.2020.1798519.

109.

Sriwijitalai W, Wiwanitkit V. Hearing loss and COVID-19: a note. Am J Otolaryngol. 2020:102473. https://doi.org/10.1016/j.amjoto.2020.102473.

110.

Abdel Rhman S, Abdel Wahid A. COVID -19 and sudden sensorineural hearing loss, a case report. Otolaryngol Case Report. 2020;16:100198. https://doi.org/10.1016/j.xocr.2020.100198.CrossRef

111.

Kilic O, Kalcioglu MT, Cag Y, Tuysuz O, Pektas E, Caskurlu H, et al. Could sudden sensorineural hearing loss be the sole manifestation of COVID-19? An investigation into SARS-COV-2 in the etiology of sudden sensorineural hearing loss. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020;97:208–11. https://doi.org/10.1016/j.ijid.2020.06.023.CrossRef

112.

Degen C, Lenarz T, Willenborg K. Acute profound sensorineural hearing loss after COVID-19 pneumonia. Mayo Clin Proc. 2020;95(8):1801–3. https://doi.org/10.1016/j.mayocp.2020.05.034.CrossRefPubMedPubMedCentral

113.

Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. Lancet Neurol. 2011;10(10):931–41. https://doi.org/10.1016/s1474-4422(11)70178-8.CrossRefPubMed

114.

Hough CL, Steinberg KP, Taylor Thompson B, Rubenfeld GD, Hudson LD. Intensive care unit-acquired neuromyopathy and corticosteroids in survivors of persistent ARDS. Intensive Care Med. 2009;35(1):63–8. https://doi.org/10.1007/s00134-008-1304-4.CrossRefPubMed

115.

Frithiof R, Rostami E, Kumlien E, Virhammar J, Fällmar D, Hultström M, et al. Critical illness polyneuropathy and myopathy in COVID-19 patients: a prospective observational intensive care unit cross-sectional cohort study. Research Square. 2020. https://doi.org/10.21203/rs.3.rs-78038/v1.

116.

Tankisi H, Tankisi A, Harbo T, Markvardsen LK, Andersen H, Pedersen TH. Critical illness myopathy as a consequence of Covid-19 infection. Clin Neurophysiol. 2020;131(8):1931–2. https://doi.org/10.1016/j.clinph.2020.06.003.CrossRefPubMedPubMedCentral

117.

Bagnato S, Boccagni C, Marino G, Prestandrea C, D’Agostino T, Rubino F. Critical illness myopathy after COVID-19. Int J Infect Dis. 2020;99:276–8. https://doi.org/10.1016/j.ijid.2020.07.072.CrossRefPubMedPubMedCentral

118.

Al-Ani F, Chehade S, Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb Res. 2020;192:152–60. https://doi.org/10.1016/j.thromres.2020.05.039.CrossRefPubMedPubMedCentral

119.

Fernandez CE, Franz CK, Ko JH, Walter JM, Koralnik IJ, Ahlawat S, et al. Imaging review of peripheral nerve injuries in patients with COVID-19. Radiology. 2020:203116. https://doi.org/10.1148/radiol.2020203116.

120.

Moghadam VD, Shafiee H, Ghorbani M, Heidarifar R. Prone positioning in management of COVID-19 hospitalized patients. Braz J Anesthesiol. 2020;70(2):188–90. https://doi.org/10.1016/j.bjane.2020.05.001.CrossRefPubMedPubMedCentral

121.

Roth C, Ferbert A, Deinsberger W, Kleffmann J, Kästner S, Godau J, et al. Does prone positioning increase intracranial pressure? A retrospective analysis of patients with acute brain injury and acute respiratory failure. Neurocrit Care. 2014;21(2):186–91. https://doi.org/10.1007/s12028-014-0004-x.CrossRefPubMed

122.

Goettler CE, Pryor JP, Reilly PM. Brachial plexopathy after prone positioning. Critical care (London, England). 2002;6(6):540–2. https://doi.org/10.1186/cc1823.CrossRefPubMedCentral

123.

Decavel P, Petit C, Tatu L. Tapia syndrome at the time of the COVID-19 pandemic: lower cranial neuropathy following prolonged intubation. Neurology. 2020;95(7):312–3. https://doi.org/10.1212/wnl.0000000000010011.CrossRefPubMed

124.

Malik GR, Wolfe AR, Soriano R, Rydberg L, Wolfe LF, Deshmukh S, et al. Injury-prone: peripheral nerve injuries associated with prone positioning for COVID-19-related acute respiratory distress syndrome. Br J Anaesth. 2020;125(6):e478–e80. https://doi.org/10.1016/j.bja.2020.08.045.CrossRefPubMedPubMedCentral

125.

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. NEJM. 2020;383(27):2603–15. https://doi.org/10.1056/NEJMoa2034577.CrossRefPubMed

126.

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. NEJM. 2020. https://doi.org/10.1056/NEJMoa2035389.

127.

FDA. Vaccines and related biological products Advisory Committee meeting December 10, 2020. FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. 2020. https://www.fda.gov/media/144245/download. Accessed Jan 3 2021.

128.

FDA. Vaccines and related biological products Advisory Committee meeting December 17, 2020. FDA briefing document Moderna COVID-19 vaccine. December 17, 2020. 2020. https://www.fda.gov/media/144434/download. Accessed Jan 3 2021.

Title: Peripheral Nervous System Manifestations Associated with COVID-19
Authors: Sasan Andalib
José Biller
Mario Di Napoli
Narges Moghimi
Louise D McCullough
Clio A. Rubinos
Christa O’Hana Nobleza
M. Reza Azarpazhooh
Luciana Catanese
Isabel Elicer
Mostafa Jafari
Fabrizio Liberati
Claudia Camejo
Michel Torbey
Afshin A. Divani
Publication date: 01-03-2021
Publisher: Springer US
Keywords: Myasthenia Gravis
Guillain-Barré Syndrome
Myalgie
Myalgia
SARS-CoV-2
COVID-19
Published in: Current Neurology and Neuroscience Reports / Issue 3/2021
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-021-01102-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Peripheral Nervous System Manifestations Associated with COVID-19

Abstract

Purpose of Review

Recent Findings

Summary

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2021

Challenges and Opportunities in Multimodal Monitoring and Data Analytics in Traumatic Brain Injury

Frameworks for Parkinson’s Disease Rehabilitation Addressing When, What, and How

Primary Progressive Aphasia: Toward a Pathophysiological Synthesis

Genetic ataxias: update on classification and diagnostic approaches

Genetic Dystonias: Update on Classification and New Genetic Discoveries

Huntington’s Disease: New Frontiers in Therapeutics